Mabylon presents novel allergen-neutralization approach at the Food Allergy Science Initiative (FASI 10) at the Broad Institute
Mabylon AG was invited to present its novel allergen-neutralization approach at FASI’s 10-Year Anniversary Research Summit at the Broad Institute.
CSO Niccolo Pengo presented Mabylon’s work on long-acting, multispecific, human-derived antibodies designed to neutralize allergens before they can trigger the allergic cascade.
The approach differs from traditional desensitization strategies in that it targets the allergens themselves rather than endogenous immune pathways or repeatedly exposing patients to the allergen. Mabylon’s antibodies are designed to provide prophylactic protection and sustained efficacy with only a few subcutaneous injections. Read more…
1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson’s Disease Candidate ‘1ST-104’
— Deal valued at up to $314.8 million, including milestones, with a separate $2.2 million strategic equity investment
— Collaboration leverages 1STBIO’s Type 2 LRRK2/c-Abl dual inhibitor to advance next-generation Parkinson’s treatment
1ST Biotherapeutics, Inc. (“1STBIO”) and SK Biopharmaceuticals Co., Ltd. (“SKBP”) today announced that they have entered into an exclusive global licensing agreement and strategic equity investment (SI) partnership to advance 1ST-104, a novel drug candidate for the treatment of Parkinson’s disease.
Omnix Medical Launches New Horizon Europe PEPTAMR Infectious Disease Consortium
- EUR ~8M grant supports the late-stage clinical development of Omnix’s antimicrobial OMN6
- Leading European partners join forces to advance OMN6 for the treatment of life-threatening hospital-acquired infections
JERUSALEM, Israel, July 13, 2026 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced the launch of the PEPTAMR consortium, bringing together leading European clinical, scientific, and academic partners to accelerate the late-stage clinical development of OMN6, its lead antimicrobial peptide targeting resistant hospital-acquired infections (HAIs), including carbapenem-resistant Acinetobacter baumannii (CRAB), a WHO critical-priority pathogen associated with mortality rates of up to 60% and severely limited treatment options. Read more…
